Capstan Launches, Backed By Big Names And Big Pharma, To Pioneer In Vivo Cell Therapies

Focused on Combining mRNA and CAR technologies

 
• By Jessica Merrill
  
Generate a summary of this article
Listen to this article
Beta

The start-up, founded on science from the University of Pennsylvania, announced a $102m series A financing and the appointment of former Silverback CEO Laura Shawver as CEO.

Two Roads
Capstan Is combining mRNA and CAR technology. • Source: Shutterstock

Capstan Therapeutics is advancing first-in-class in vivo chimeric antigen receptor (CAR) therapies that could have applicability across a wide range of therapeutic areas from a high-profile team of founding scientists, with financing from a cross-section of big pharma names and venture capital firms. The goal is to combine mRNA and CAR technologies to develop cell therapies that can be easily administered to patients.

The company announced a $102m series A financing on 14 September, building on a $63m seed funding round late last...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Start-Ups & SMEs

Scrip-Business (Free-1): Top-Selling Drugs 2024: Keytruda, Ozempic And Dupixent Dominate

 
• By Nabil

Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.

Pentixapharm Poised To Make A Splash In The Radiopharmaceuticals Pool

 
• By Kevin Grogan

The German group is spinning off from Eckert & Ziegler and listing in Frankfurt, though a leap to the NASDAQ will likely follow once it has more data on a lymphoma theranostic.

Finance Watch: GondolaBio, BridgeBio’s Second Spinout Of 2024, Launches With $300m

 
• By Mandy Jackson

BridgeBio spun out oncology assets in May to focus on rare diseases and now it has sliced off a few rare disease candidates for GondolaBio. Also, Avidity and Kymera closed follow-on offerings that grossed $345.1m and $225m, respectively, and Vandria extended its series A round to $30.7m.

Borealis Seeks Aurora In RNA-Based Drugs For Renal Disease

 
• By Alaric DeArment

With $150m in series A funding, the Versant- and Novartis-backed start-up is betting it can overcome the challenges to getting RNA medicines into the kidney.

More from Business

How A New Healthcare Dialogue Is Driving Market Access In Mexico

Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.